Moolec Science (MLECW) Receivables (2022 - 2025)
Moolec Science (MLECW) posted Receivables of $19.9 million for Q2 2025, up 627.91% sequentially from $2.7 million in Q4 2024, and down 91.82% YoY from $243.7 million in Q2 2024.
Moolec Science (MLECW) Receivables (2022 - 2025) Analysis & Trends
Moolec Science has reported Receivables for 4 years, with the latest figure at $19.9 million in Q2 2025.
- Quarterly Receivables fell 91.82% year-over-year to $19.9 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $19.9 million (down 91.82% YoY) and the FY2025 annual result came in at $19.9 million, down 91.82% from the prior year.
- Receivables advanced to $19.9 million in Q2 2025 per MLECW's latest filing, from $2.7 million in the prior quarter.
- Over five years, Receivables peaked at $243.7 million in Q2 2024 and troughed at $4122.0 in Q2 2022.
- A 4-year average of $28.1 million and a median of $8.1 million in 2022 frame the typical range for Receivables.
- The sharpest annual moves came in 2023 and 2025: Receivables surged 221251.87% in 2023, then tumbled 91.82% in 2025.
- Over 4 years, Receivables stood at $8.1 million in 2022, then tumbled by 85.13% to $1.2 million in 2023, then soared by 128.16% to $2.7 million in 2024, then surged by 627.91% to $19.9 million in 2025.
- According to Business Quant data, Receivables over the past three periods registered $19.9 million, $2.7 million, and $1.6 million for Q2 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 19.93 Mn |
| Dec 31, 2024 | 2.74 Mn |
| Sep 30, 2024 | 1.62 Mn |
| Jun 30, 2024 | 243.66 Mn |
| Mar 31, 2024 | 1.74 Mn |
| Dec 31, 2023 | 1.20 Mn |
| Sep 30, 2023 | 12.23 Mn |
| Jun 30, 2023 | 9.12 Mn |
| Mar 31, 2023 | 9.11 Mn |
| Dec 31, 2022 | 8.07 Mn |
| Jun 30, 2022 | 4,122.00 |